An independent source of information on U.S. brand name drugs for health professionals

Drugdocs Logo

An independent source of information on U.S. brand name drugs for health professionals

HomeDrugsGlossaryAboutContact Us

Menu

HomeDrugsGlossaryAboutContact Us

Drugs A-Z

ABCDE FGHIJKLMNOPQRSTUVWXYZ

DRUGS

A

B

C

D

E

F

G

H

I

J

K

L

M

N

O

P

Q

R

S

T

U

V

W

X

Y

Z

Cotellic

Chemical Namecobimetinib
Dosage FormTablet (oral; 20 mg)
Drug ClassKinase inhibitors
SystemSkin
CompanyGenentech Inc.
Approval Year2015

Indication

  • To be used in combination with vemurafenib to treat advanced melanoma that has spread to other parts of the body or can’t be removed by surgery, and that has a certain type of abnormal gene (BRAF V600E or V600K mutation)
Last updated on 10/30/2020

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Cotellic (cobimetinib) Prescribing Information 2018Genentech USA, Inc., South San Francisco, CA
Document TitleYearSource
Cobimetinib in combination with vemurafenib for treating unresectable or metastatic BRAF V600 mutation-positive melanoma. 2016NICE
Document TitleYearSource
Systemic therapy for melanoma: ASCO Guideline. 2020Journal of Clinical Oncology